Orbital metastasis as the primary manifestation of pancreatic carcinoma: a case report and literature review

Tatsuro Yokoyama1, Aric Vaidya1,2, Hirohiko Kakizaki1 and Yasuhiro Takahashi1*

Abstract

Background: Orbital metastasis from pancreatic tumors is extremely rare, and its clinical characteristics are still unclear.

Case presentation: Our case was a 73-year-old female who noticed diplopia on right gaze 3 months before referral to us. Imaging studies demonstrated a mass involving the lateral rectus muscle in the right orbit. The results of pathological examination of an excised specimen corresponded to poorly differentiated adenocarcinoma. Systemic work-up revealed pancreatic carcinoma with peritoneal metastasis. The patient underwent chemotherapy. We reviewed literature on similar cases and found 19 reported cases of pancreatic tumors metastasizing to the orbit. The results of our review indicate a tendency for formation of solitary mass without bony erosion, delayed detection of the primary pancreatic carcinoma, and poorer prognosis of such tumors, compared to metastatic orbital tumors from other lesions.

Conclusions: We report a rare case of metastatic orbital tumor from an unknown primary pancreatic carcinoma. Clinical characteristics of cases with metastatic pancreatic tumors seem to be different from those with metastatic tumors from the other lesions. Pancreatic tumors are frequently asymptomatic in an early stage, leading to delayed detection of the primary pancreatic carcinoma and poorer prognosis.

Keywords: Pancreatic carcinoma, Metastatic orbital tumor, Diplopia, Proptosis

Background

Metastatic orbital tumors are rare entities and account for 1.5 to 12% of orbital tumors [1]. The common primary sites of these tumors are the breast, lung, prostate, and skin (melanoma) [1–6]. On the contrary, orbital metastasis from pancreatic tumors is extremely rare.

Here, we report a rare case of metastatic orbital tumor from pancreatic carcinoma without a known history of a primary lesion at the initial presentation and the result of our literature review.

Case presentation

A 73-year-old female complained of diplopia on right gaze 3 months before referral to us. She was consulted with a neurosurgeon at another hospital, who suspected right 6th cranial nerve palsy. Magnetic resonance imaging (MRI) showed a right orbital mass. The doctor followed-up her for 1 month, but the restriction of abduction deteriorated and there was development of proptosis on the right side. She did not have any history of ocular or systemic disease, or family history.

On the first examination, her best-corrected visual acuity was 1.0 in both eyes. Intraocular pressure was 13 mmHg in the right eye and 14 mmHg in the left eye. She did not have any field of binocular single vision in all directions of gaze, and the Hess chart showed severe...
restriction of adduction and abduction. There was no palpable periocular mass. The Hertel exophthalmometric examination demonstrated measurements of 20.5 mm on the right side and 15.5 mm on the left side (base, 102.5 mm) (Fig. 1a).

Computed tomographic (CT) images showed a mass in the right orbit involving the lateral rectus muscle without bony erosion (Fig. 1b). MRI revealed a mass involving the lateral rectus muscle with iso-intensity to the gray matter on T1-weighted image and heterogenous iso-to-high intensity to the gray matter on T2-weighted image. Enhanced T1-weighted MRI showed strong enhancement, especially in the peripheral part of the mass (Fig. 1c).

An excisional biopsy of the mass was performed under general anesthesia by two of the authors (YT and AV). The results of pathological examination corresponded to poorly differentiated adenocarcinoma (Fig. 1d), but the primary site was undetermined.

Systemic CT showed enlargement of the pancreatic tail with pancreatic duct dilation and small nodules in the mesenteric membrane (Fig. 1e), suspecting pancreatic carcinoma with peritoneal metastasis. The patient was consulted with a gastrointestinal physician for further examination. Blood tests demonstrated elevated carbohydrate antigen 19–9 (CA 19–9; 1141 U/mL; normal limit, <37 U/mL), Span-1 (130 U/mL; normal limit, <30 U/mL), carcinoembryonic antigen (CEA; 5.4 ng/mL; normal range, 0.1–5.0 ng/mL), and immunoglobulin G4 (681 mg/mL; normal limit, <135 mg/mL). Magnetic resonance cholangiopancreatography demonstrated an enlargement of the pancreatic tail. The pancreatic duct was not depicted in the tail of pancreas but was dilated in the pancreatic body. Fine needle aspiration biopsy of the pancreatic lesion pathologically revealed the same findings to the orbital tumor.

After induction chemotherapy using FOLFIRINOX regimen at our hospital, the patient was transferred to another hospital to continue chemotherapy.

Discussion
This report highlighted a rare case of metastatic orbital tumor from an occult pancreatic carcinoma. We reviewed literature on orbital metastasis of pancreatic tumors and found 19 reported cases (Table 1), but some of the reports did not present the details of clinical findings [7–20]. We did not include a case of uveal metastasis of pancreatic tumor in this review [21]. Pathological results included adenocarcinoma, islet cell carcinoma, and carcinoid tumor/neuroendocrine neoplasm [12–15, 17–20].
Table 1  Summary of the previously reported cases of metastatic pancreatic carcinoma to the orbit

| Authors (Year) | Age | Sex | Side | Past history | Known primary pancreatic carcinoma (if yes, duration from diagnosis of primary carcinoma to onset) | Period from onset to first examination | Symptoms | Imaging modality | Location | Diagnostic procedure | Pathology | Other distant metastatic lesions | Treatment | Clinical course |
|---------------|-----|-----|------|--------------|------------------------------------------------------------------------------------------------|---------------------------------------|----------|-----------------|----------|-------------------|-----------|-------------------------------|-----------|------------------|
| Ferry et al. (1974) / Font et al. (1976) | - | M | - | - | - | - | - | - | - | - | - | - | - | - |
| Hutchison et al. (1979) | - | M | - | - | - | - | - | - | - | - | - | - | - | - |
| Castro et al. (1982) | - | M | - | - | - | - | - | - | - | - | - | - | - | - |
| Goldborger et al. (1990) | 51 | F | L | - | N | - | Eyelid edema, hyperemia, induction, motility disturbance, pain | - | - | - | - | - | - | - | Death 1 month after presenting with orbital metastasis |
| Geetha et al. (1998) | 38 | M | R | Nil | N | 1 month | Pain, redness, diplopia, decreased vision, enophthalmos | CT | Poorly differentiated adenocarcinoma | Nil | Palliative treatment | - | - |
| Chand et al. (1998) | 52 | M | L | Nil | N | 1 month | Proptosis, decreased vision | CT | Poorly differentiated adenocarcinoma | Liver | - | - | - |
| Gerwald et al. (2000) | 53 | F | R | Nil | N | Y (unknown) | Most recent | Headache, swelling, proptosis, diplopia, partial visual loss | CT/MRI | Islet cell carcinoma | Liver, bone | Post-chemotherapy on first examination | No recurrence at 6 months follow-up |
| Couch (2000) | 42 | F | L | Nil | Y (4 years) | a few weeks | Visual loss, diplopia, proptosis | MRI | Carcinoid tumor, breast, liver, and mesenteric lymph nodes | Surgical debulking | Radiation and additional debulking | - | Death after 14 years after initial presentation |
| Amemiya et al. (2002) | 51-68 | M | R/L | - | - | - | Proptosis, limited ocular movement, palpbral tumor | - | - | - | - | - | - | Death 7 months after onset in one patient |
| Foo et al. (2010) | 71 | M | L | Left frontal convexity meningioma | N | 6 months | Blurred vision, supraorbital ache, diplopia | CT/MRI | Adenocarcinoma | Nil | Radiation to the orbit | Death after 4 weeks |
| Pecen et al. (2012) | 59 | M | R | Nil | N | 4 weeks | Diplopia, eyelid swelling, proptosis, proptosis | MRI | Superior orbit | Excisional biopsy | Poorly differentiated adenocarcinoma | Liver, lymph nodes | Palliative treatment | Death 7 months after first examination |
| Kamieniarz (2020) | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Authors (Year) | Age | Sex | Side | Past history | Known primary pancreatic carcinoma (if yes, duration from diagnosis of primary carcinoma to onset) | Period from onset to first examination | Symptoms | Imaging modality | Location | Diagnostic procedure | Pathology | Other distant metastatic lesions | Treatment | Clinical course |
|---------------|-----|-----|------|--------------|-------------------------------------------------------------------------------------------------|--------------------------------------|----------|-----------------|----------|---------------------|-----------|------------------------|-----------|-----------------|
| Tsai (2021)   | 60  | M   | R    | Nil          | Y (1 year)                                                                                       | 3 months                            | Headache, blurred vision, proptosis, ptosis, ocular pain | CT       | Infero-posterior orbital space | Biopsy   | Adenocarcinoma from ampulla of Vater | Multiple metastasis | High-dose 5-FU | Death 1 month later |

*M* Male, *F* Female, *R* Right, *L* Left, *Y* Yes, *N* No, *CT* Computed tomography, *MRI* Magnetic resonance imaging, *FNA* Fine needle aspiration
The male to female ratio among 16 patients, including our patient with metastasis of pancreatic tumors to the orbit was 5:3, and the mean age of 11 patients was 56.2 years [7–18, 20]. These were similar to the results obtained from all the patients of orbital metastatic tumors [6, 11].

The right to left ratio among 11 patients, including our patient was almost 1:1, [11–18, 20] indicating no side-related predominance regarding orbital metastasis of pancreatic tumors.

The primary tumors are diagnosed before the onset of orbital metastasis in 85% of cases [6]. This may be due to increase in awareness and advances in medicine for early detection of malignant tumors [1, 6]. However, orbital metastasis preceded detection of the primary pancreatic carcinoma in 6 of 9 patients (66.7%) [11–15, 17, 18, 20]. This may be caused by minimal symptoms related to early stage of pancreatic carcinoma in most of the cases.

Typical radiographic findings of metastatic orbital tumors are intramuscular focal masses, bone destruction, and diffuse intraocular lesions; while a focal, solitary mass is atypical [4]. The superior and lateral quadrants of the orbit are the common regions for orbital metastasis [1]. Seven cases of metastasis of pancreatic tumors, including our case, showed a solitary mass located superiorly in 2 cases, [12, 18] medially in 1 case [15], supero-medially in 1 case [13], inferiorly in 1 case [20], supero-laterally in 1 case [14], and laterally in 1 cases [17]. Although some of the tumors involved the extraocular muscle, an intramuscular focal mass was suspected only in our case. Bone was eroded only in 1 case [14]. These results indicate that metastatic tumors of pancreatic cancer may have a tendency to show a solitary mass without bony erosion.

Symptoms and signs of orbital metastasis include proptosis/enophthalmos, diplopia, pain, vision loss, ptosis, palpable mass, subconjunctival hemorrhage, and chemosis. Proptosis and diplopia are the most common symptoms, but the manifestation of these symptoms and signs depend on the location and size of tumors [1]. Among 11 cases of metastasized pancreatic tumors, [11–18, 20] diplopia/extraocular muscle motility disturbance was the most common symptom (81.8%). Six of the 11 cases had decreased vision. Although 8 cases showed proptosis, 1 had enophthalmos. The tendency of ocular symptoms in cases of metastasized pancreatic cancer appears to be similar to that in cases of metastatic tumors from other lesions.

The prognosis in cases with orbital metastasis is generally poor [5]. The average survival for all cases is 9.3–25 months [1–3]. A previous study showed that all patients followed-up for at least 4.5 years had died at the end of the study [5]. The mean survival time tends to be longer in patients with primary breast cancer [5]. Among 7 cases of metastasized pancreatic tumors, one patient died 14 years after the initial examination [15], and another patient showed no recurrence at 6 months follow-up [14]. On the contrary, 3 patients died at 4 weeks/1 month follow-up [11, 17, 20], and the other 2 patients died 7 months after the onset or first examination [16, 18]. In addition, among 10 cases, 8 cases (80.0%) demonstrated other distant metastatic lesions [12–18, 20]. The minimal symptoms related to pancreatic carcinoma may permit insidious disease progress, resulting in poorer prognosis compared to other metastatic tumors. However, recent development of treatment modalities, such as immune checkpoint inhibitors and molecular targeted drugs may improve the survival rate.

In conclusion, we report a case of metastatic pancreatic carcinoma to the orbit and the results of literature review. Pancreatic tumors are frequently asymptomatic in an early stage, leading to delayed detection of the primary pancreatic carcinoma and poorer prognosis compared to other metastatic orbital tumors.

Abbreviations
CT: Computed tomography; CA 19–9: Carbohydrate antigen 19–9; CEA: Carcino-embryonic antigen.

Acknowledgements
Other contributors
No one contributed to the work who did not meet our authorship criteria.

Authors’ contributions
YT designed the present study. Data collection was done by YT. Literature search was done by YT, TY, AV, HK, and YT interpreted data. TY and YT drafted the word. AV and HK revised the work. All authors read and approved the final manuscript.

Funding
None.

Availability of data and materials
All data are included in this paper.

Declarations
Ethics approval and consent to participate
This case report adheres to the tenets of the 1964 Declaration of Helsinki. We asked the institutional review board of Aichi Medical University Hospital and confirmed that the ethics approval for this report was not necessary on the basis of the ethical guidelines for medical and health research involving human subjects established by the Japanese Ministry of Education, Culture, Sports, Science, and Technology and the Ministry of Health, Labour, and Welfare.

Consent for publication
Written informed consent for the publication of this report and identifiable patient photos were obtained from the patient.

Competing interests
No authors have any conflicting interests to disclose.

Author details
1 Department of Oculoplastic, Orbital & Lacrimal Surgery, Aichi Medical University Hospital, 1-1 Yazako-Karimata, Nagakute, Aichi 480-1195, Japan.
Department of Oculoplastic, Orbital & Lacrimal Surgery, Kirtipur Eye Hospital, Kathmandu, Nepal.

Received: 4 November 2021  Accepted: 4 March 2022
Published online: 12 March 2022

References
1. Goldberg RA, Rootman J, Cline RA. Tumors metastatic to the orbit: a changing picture. Surv Ophthalmol. 1990;35:1–24.
2. Shields JA, Shields CL, Brotman HK, Carvalho C, Perez N, Eagle RC. Jr. Cancer metastatic to the orbit: the 2000 Robert M Cruz Lecture. Ophthalmic Plast Reconstr Surg. 2001;17:346–54.
3. Tijl J, Koornneef L, Eijpe A, Thomas L, Gonzalez DG, Veenhof C. Metastatic tumors to the orbit – management and prognosis. Graefes Arch Clin Exp Ophthalmol. 1992;230:527–30.
4. Char DH, Miller T, Kroll S. Orbital metastasis: diagnosis and course. Br J Ophthalmol. 1997;81:386–90.
5. Freedman MI, Folk JC. Metastatic tumors to the eye and orbit: patient survival and clinical characteristics. Arch Ophthalmol. 1987;105:1215–9.
6. Valenzuela AA, Archibald CW, Fleming B, Ong L, O’Donnell B, Crompton J, Selva D, McNab AA, Sullivan TJ. Orbital metastasis: clinical features, management and outcome. Orbit. 2009;28:153–9.
7. Ferry AP, Font RL. Carcinoma metastatic to the eye and orbit. I. Clinicopathologic study of 227 cases. Arch Ophthalmol. 1974;92:276–86.
8. Font RL, Ferry AP. Carcinoma metastatic to the eye and orbit. III. A clinicopathologic study of 28 cases metastatic to the orbit. Cancer. 1976;38:1326–35.
9. Hutchison DS, Smith TR. Ocular and orbital metastatic carcinoma. Ann Ophthalmol. 1979;11:869–73.
10. Castro PA, Albert DM, Wang WJ, Ni C. Tumors metastatic to the eye and adnexa. Int Ophthalmol Clin. 1982;22:189–223.
11. Goldberg RA, Rootman J. Clinical characteristics of metastatic orbital tumors. Ophthalmology. 1990;97:620–4.
12. Geetha N, Chandralakha B, Kumar A, Ittyavirah AK, Ramadas K, Joseph F. Carcinoma of the pancreas presenting as an orbital tumor: a case report. Am J Clin Oncol. 1998;21:532–3.
13. Chand K, Panicker NK. Proptosis - an unusual presentation of metastatic carcinoma pancreas. Med J Armed Forces India. 1998;54:349–50.
14. Gotwald TF, Zirnreich SJ, Schocke M, Frede T, Bellmann R, Zur ND. CT and MR imaging of orbital metastasis from islet cell carcinoma of the pancreas. Am J Roentgenol. 2000;175:475–6.
15. Couch DA, O’Halloran HS, Hansworth KM, Cowen DE, Baker RS. Carcinoïd metastasis to extraocular muscles: case reports and review of the literature. Orbit. 2000;19:263–9.
16. Amemiya T, Hayashida H, Dake Y. Metastatic orbital tumors in Japan: a review of the literature. Ophthalmic Epidemiol. 2002;9:35–47.
17. Foo FY, Lee M, Looi A. Asymptomatic pancreatic adenocarcinoma presenting as an orbital metastatic tumor. Orbit. 2010;29:262–5.
18. Pecen PE, Ramey NA, Richard MJ, Bhatti MT. Metastatic pancreatic carcinoma to the orbital apex presenting as a superior divisional third cranial nerve palsy. Clin Ophthalmol. 2012;6:1941–3.
19. Kamieniarz L, Armreni E, O’Mahony LF, Leigh C, Miah L, Narayan A, Bhatt A, Cox N, Mandair D, Navakkosoor S, Caplin M, Tsompanakis C. Orbital metastases from neuroendocrine neoplasms: clinical implication and outcomes. Endocrine. 2020;67:485–93.
20. Tsai TE, Chien KH, Li YF, Lai SW. Rare orbital metastasis originating from ampullary adenocarcinoma. Medicine. 2021;57:1238.
21. Hart WM. Metastatic carcinoma to the eye and orbit. Int Ophthalmol Clin. 1962;2:465–82.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.